← Scilex Holding Company (SCLX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Scilex Holding Company (SCLX)
Biological Products, (No Diagnostic Substances) · market cap $45M · as of 2026-07-15
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-13 (est.)
Earnings
Pipeline
2
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Scilex Holding Company (SCLX) is a small-cap specialty pharmaceutical company with a market cap of approximately $80M, focused on pain management. Its lead asset, SP-102, is in Phase 3 for lumbosacral radicular pain, with a secondary pipeline asset SP-103 in Phase 2 for moderate to severe acute lower back pain. The company is in a precarious financial position, carrying $3.4M in cash, $77.4M in net debt, and an estimated 9-month runway.
The catalyst path
- 2026-11-13 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| SP-102 | Phase 3 | Lumbosacral Radicular Pain |
| SP-103 | Phase 2 | Moderate to Severe Acute Lower Back Pain |
Price & technical context
3-month
-45.6%
6-month
-5.2%
12-month
-65.9%
52-wk range
$3.69–$14.02
vs 50-day MA
-23.3%
vs 200-day MA
-25.4%
Realized vol
99.0%
Max drawdown
-92.3%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for SCLX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.